{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:22:00Z","timestamp":1782325320043,"version":"3.54.5"},"reference-count":76,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a common neurodegenerative disorder characterized by misfolding of \u03b1-synuclein. Clinical manifestations include slowly developing resting tremor, muscle rigidity, bradykinesia and abnormal gait. The pathological mechanisms underlying PD are complex and yet to be fully elucidated. Clinical studies suggest that the onset of gastrointestinal symptoms may precede motor symptoms in PD patients. The microbiota-gut-brain axis plays a bidirectional communication role between the enteric nervous system and the central nervous system. This bidirectional communication between the brain and gut is influenced by the neural, immune and endocrine systems related to the gut microbiome. A growing body of evidence indicates a strong link between dysregulation of the gut microbiota and PD. In this review, we present recent progress in understanding the relationship between the microbiota-gut-brain axis and PD. We focus on the role of the gut microbiota, the unique changes observed in the microbiome of PD patients, and the impact of these changes on the progression of PD. Finally, we evaluate the role of current treatment strategies for PD, including probiotics, fecal microbial transplants, dietary modifications, and related drug therapies.<\/jats:p>","DOI":"10.31083\/j.jin2206157","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:48:50Z","timestamp":1698716930000},"source":"Crossref","is-referenced-by-count":21,"title":["Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease"],"prefix":"10.31083","volume":"22","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chengdu Second People's Hospital, 610017 Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Song","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cangxi People's Hospital, 628400 Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Sang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhong","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijing","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The People's Hospital of Kaizhou District, 405400 Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"ref1","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018; 17: 939\u2013953."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Warnecke T, Sch\u00e4fer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management. Journal of Parkinson\u2019s Disease. 2022; 8: 31.","DOI":"10.1038\/s41531-022-00295-x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Szandruk-Bender M, Wiatrak B, Szel\u0105g A. The Risk of Developing Alzheimer\u2019s Disease and Parkinson\u2019s Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis. Journal of Clinical Medicine. 2022; 11: 3704.","DOI":"10.3390\/jcm11133704"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997; 388: 839\u2013840.","DOI":"10.1038\/42166"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nature Neuroscience. 2018; 21: 1341\u20131349.","DOI":"10.1038\/s41593-018-0238-6"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiology of Aging. 2003; 24: 197\u2013211.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease. Neurology. 2017; 88: 1996\u20132002.","DOI":"10.1212\/WNL.0000000000003961"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Horsager J, Andersen KB, Knudsen K, Skj\u00e6rb\u00e6k C, Fedorova TD, Okkels N, et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020; 143: 3077\u20133088.","DOI":"10.1093\/brain\/awaa238"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nash MJ, Frank DN, Friedman JE. Early Microbes Modify Immune System Development and Metabolic Homeostasis-The \u201cRestaurant\u201d Hypothesis Revisited. Frontiers in Endocrinology. 2017; 8: 349.","DOI":"10.3389\/fendo.2017.00349"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cheng J, Ringel-Kulka T, Heikamp-de Jong I, Ringel Y, Carroll I, de Vos WM, et al. Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children. the ISME Journal. 2016; 10: 1002\u20131014.","DOI":"10.1038\/ismej.2015.177"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Karl JP, Hatch AM, Arcidiacono SM, Pearce SC, Pantoja-Feliciano IG, Doherty LA, et al. Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota. Frontiers in Microbiology. 2018; 9: 2013.","DOI":"10.3389\/fmicb.2018.02013"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, et al. Metagenomics of Parkinson\u2019s disease implicates the gut microbiome in multiple disease mechanisms. Nature Communications. 2022; 13: 6958.","DOI":"10.1038\/s41467-022-34667-x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019; 7: 14.","DOI":"10.3390\/microorganisms7010014"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jacobson A, Yang D, Vella M, Chiu IM. The intestinal neuro-immune axis: crosstalk between neurons, immune cells, and microbes. Mucosal Immunology. 2021; 14: 555\u2013565.","DOI":"10.1038\/s41385-020-00368-1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hattori N, Yamashiro Y. The Gut-Brain Axis. Annals of Nutrition and Metabolism. 2021; 77: 1\u20133.","DOI":"10.1159\/000512226"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Spichak S, Bastiaanssen TFS, Berding K, Vlckova K, Clarke G, Dinan TG, et al. Mining microbes for mental health: Determining the role of microbial metabolic pathways in human brain health and disease. Neuroscience and Biobehavioral Reviews. 2021; 125: 698\u2013761.","DOI":"10.1016\/j.neubiorev.2021.02.044"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterology Clinics of North America. 2017; 46: 77\u201389.","DOI":"10.1016\/j.gtc.2016.09.007"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pascale A, Marchesi N, Govoni S, Barbieri A. Targeting the microbiota in pharmacology of psychiatric disorders. Pharmacological Research. 2020; 157: 104856.","DOI":"10.1016\/j.phrs.2020.104856"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host and Microbe. 2018; 23: 716\u2013724.","DOI":"10.1016\/j.chom.2018.05.003"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, T\u00f3th M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Science Translational Medicine. 2014; 6: 263ra158.","DOI":"10.1126\/scitranslmed.3009759"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P. Is Parkinson\u2019s disease a chronic low-grade inflammatory bowel disease? Journal of Neurology. 2020; 267: 2207\u20132213.","DOI":"10.1007\/s00415-019-09321-0"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti\u2013Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease among Patients with Inflammatory Bowel Disease. JAMA Neurology. 2018; 75: 939.","DOI":"10.1001\/jamaneurol.2018.0605"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Werner T, Horvath I, Wittung-Stafshede P. Crosstalk between Alpha-Synuclein and other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson\u2019s Disease. Journal of Parkinson\u2019s Disease. 2020; 10: 819\u2013830.","DOI":"10.3233\/JPD-202085"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Miller AL, Bessho S, Grando K, T\u00fckel \u00c7. Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Frontiers in Immunology. 2021; 12: 638867.","DOI":"10.3389\/fimmu.2021.638867"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathologica. 2019; 138: 535\u2013550.","DOI":"10.1007\/s00401-019-02040-w"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sampson TR, Challis C, Jain N, Moiseyenko A, Ladinsky MS, Shastri GG, et al. A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice. eLife. 2020; 9: e53111.","DOI":"10.7554\/eLife.53111"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nature Communications. 2019; 10: 310.","DOI":"10.1038\/s41467-019-08294-y"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shen T, Yue Y, He T, Huang C, Qu B, Lv W, et al. The Association Between the Gut Microbiota and Parkinson\u2019s Disease, a Meta-Analysis. Frontiers in Aging Neuroscience. 2021; 13: 636545.","DOI":"10.3389\/fnagi.2021.636545"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Gerhardt S, Mohajeri MH. Changes of Colonic Bacterial Composition in Parkinson\u2019s Disease and Other Neurodegenerative Diseases. Nutrients. 2018; 10: 708.","DOI":"10.3390\/nu10060708"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, et al. Gut microbiota in Parkinson\u2019s disease: Temporal stability and relations to disease progression. EBioMedicine. 2019; 44: 691\u2013707.","DOI":"10.1016\/j.ebiom.2019.05.064"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, et al. Meta-Analysis of Gut Dysbiosis in Parkinson\u2019s Disease. Movement Disorders. 2020; 35: 1626\u20131635.","DOI":"10.1002\/mds.28119"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Movement Disorders. 2019; 34: 396\u2013405.","DOI":"10.1002\/mds.27581"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Pietrucci D, Cerroni R, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, et al. Dysbiosis of gut microbiota in a selected population of Parkinson\u2019s patients. Parkinsonism and Related Disorders. 2019; 65: 124\u2013130.","DOI":"10.1016\/j.parkreldis.2019.06.003"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Disease. 2021; 7: 27.","DOI":"10.1038\/s41531-021-00156-z"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson\u2019s disease. Brain, Behavior, and Immunity. 2018; 70: 194\u2013202.","DOI":"10.1016\/j.bbi.2018.02.016"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Movement Disorders. 2017; 32: 739\u2013749.","DOI":"10.1002\/mds.26942"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lin A, Zheng W, He Y, Tang W, Wei X, He R, et al. Gut microbiota in patients with Parkinson\u2019s disease in southern China. Parkinsonism and Related Disorders. 2018; 53: 82\u201388.","DOI":"10.1016\/j.parkreldis.2018.05.007"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Li F, Wang P, Chen Z, Sui X, Xie X, Zhang J. Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson\u2019s disease. Neuroscience Letters. 2019; 707: 134297.","DOI":"10.1016\/j.neulet.2019.134297"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Li C, Cui L, Yang Y, Miao J, Zhao X, Zhang J, et al. Gut Microbiota Differs Between Parkinson\u2019s Disease Patients and Healthy Controls in Northeast China. Frontiers in Molecular Neuroscience. 2019; 12: 171.","DOI":"10.3389\/fnmol.2019.00171"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Blasco MP, Chauhan A, Honarpisheh P, Ahnstedt H, d\u2019Aigle J, Ganesan A, et al. Age-dependent involvement of gut mast cells and histamine in post-stroke inflammation. Journal of Neuroinflammation. 2020; 17: 160.","DOI":"10.1186\/s12974-020-01833-1"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Amorim Neto DP, Bosque BP, Pereira de Godoy JV, Rodrigues PV, Meneses DD, Tostes K, et al. Akkermansia muciniphila induces mitochondrial calcium overload and \u03b1-synuclein aggregation in an enteroendocrine cell line. iScience. 2022; 25: 103908.","DOI":"10.1016\/j.isci.2022.103908"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Lin CH, Chen CC, Chiang HL, Liou JM, Chang CM, Lu TP, et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson\u2019s disease. Journal of Neuroinflammation. 2019; 16: 129.","DOI":"10.1186\/s12974-019-1528-y"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Bottacini F, van Sinderen D, Ventura M. Omics of bifidobacteria: research and insights into their health-promoting activities. Biochemical Journal. 2017; 474: 4137\u20134152.","DOI":"10.1042\/BCJ20160756"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. 2005; 64: 1047\u20131051.","DOI":"10.1212\/01.WNL.0000154532.98495.BF"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, et al. Progression of Parkinson\u2019s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE. 2017; 12: e0187307.","DOI":"10.1371\/journal.pone.0187307"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Disease. 2020; 6: 11.","DOI":"10.1038\/s41531-020-0112-6"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Boertien JM, Murtom\u00e4ki K, Pereira PAB, van der Zee S, Mertsalmi TH, Levo R, et al. Fecal microbiome alterations in treatment-naive de novo Parkinson\u2019s disease. NPJ Parkinsons Disease. 2022; 8: 129.","DOI":"10.1101\/2022.02.18.22270887"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clinical Interventions in Aging. 2010; 5: 229\u2013238.","DOI":"10.2147\/CIA.S6456"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Goya ME, Xue F, Sampedro-Torres-Quevedo C, Arnaouteli S, Riquelme-Dominguez L, Romanowski A, et al. Probiotic Bacillus subtilis Protects against \u03b1-Synuclein Aggregation in C. elegans. Cell Reports. 2020; 30: 367\u2013380.e7.","DOI":"10.1016\/j.celrep.2019.12.078"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Sun J, Li H, Jin Y, Yu J, Mao S, Su KP, et al. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson\u2019s disease via gut microbiota-GLP-1 pathway. Brain, Behavior, and Immunity. 2021; 91: 703\u2013715.","DOI":"10.1016\/j.bbi.2020.10.014"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Liao JF, Cheng YF, You ST, Kuo WC, Huang CW, Chiou JJ, et al. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson\u2019s disease. Brain, Behavior, and Immunity. 2020; 90: 26\u201346.","DOI":"10.1016\/j.bbi.2020.07.036"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Castelli V, d\u2019Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson\u2019s disease models. Aging. 2020; 12: 4641\u20134659.","DOI":"10.18632\/aging.102927"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, et al. Clinical and metabolic response to probiotic administration in people with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition. 2019; 38: 1031\u20131035.","DOI":"10.1016\/j.clnu.2018.05.018"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Gulati AS, Nicholson MR, Khoruts A, Kahn SA. Fecal Microbiota Transplantation across the Lifespan: Balancing Efficacy, Safety, and Innovation. American Journal of Gastroenterology. 2023; 118: 435\u2013439.","DOI":"10.14309\/ajg.0000000000002167"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Zhao Z, Ning J, Bao X, Shang M, Ma J, Li G, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson\u2019s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021; 9: 226.","DOI":"10.1186\/s40168-021-01107-9"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Radad K, Moldzio R, Rausch W. Minocycline Protects Dopaminergic Neurons against Long-Term Rotenone Toxicity. Canadian Journal of Neurological Sciences. 2010; 37: 81\u201385.","DOI":"10.1017\/S0317167100009690"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson\u2019s disease. BMC Neuroscience. 2009; 10: 109.","DOI":"10.1186\/1471-2202-10-109"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, et al. Measuring Disease Progression in Early Parkinson Disease. JAMA Neurology. 2014; 71: 710\u2013716.","DOI":"10.1001\/jamaneurol.2014.391"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lazzarini M, Martin S, Mitkovski M, Vozari RR, St\u00fchmer W, Bel ED. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. Glia. 2013; 61: 1084\u20131100.","DOI":"10.1002\/glia.22496"},{"key":"ref60","unstructured":"Zhang GB, Feng YH, Wang PQ, Song JH, Wang P, Wang SA. A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat. European Review for Medical and Pharmacological Sciences. 2015; 19: 3468\u20133474."},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"La Vitola P, Artioli L, Cerovic M, Poletto C, Dacomo L, Leva S, et al. Repositioning doxycycline for treating synucleinopathies: Evidence from a pre-clinical mouse model. Parkinsonism and Related Disorders. 2023; 106: 105229.","DOI":"10.1016\/j.parkreldis.2022.105229"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Zhou X, Lu J, Wei K, Wei J, Tian P, Yue M, et al. Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson\u2019s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota. Oxidative Medicine and Cellular Longevity. 2021; 2021: 9424582.","DOI":"10.1155\/2021\/9424582"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. \u0392-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433: 73\u201377.","DOI":"10.1038\/nature03180"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"West CL, Mao Y, Delungahawatta T, Amin JY, Farhin S, McQuade RM, et al. Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson\u2019s Disease. Journal of Parkinson\u2019s Disease. 2020; 10: 1477\u20131491.","DOI":"10.3233\/JPD-202076"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Vel\u00e1squez-Mej\u00eda EP, Carmona JA, Abad JM, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017; 40: 54\u201362.","DOI":"10.2337\/dc16-1324"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, et al. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson\u2019s disease. Microbiome. 2021; 9: 34.","DOI":"10.1186\/s40168-020-00988-6"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Hauser RA, Sutherland D, Madrid JA, Rol MA, Frucht S, Isaacson S, et al. Targeting neurons in the gastrointestinal tract to treat Parkinson\u2019s disease. Clinical Parkinsonism and Related Disorders. 2019; 1: 2\u20137.","DOI":"10.1016\/j.prdoa.2019.06.001"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Zhao Z, Li F, Ning J, Peng R, Shang J, Liu H, et al. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4\/MyD88\/NF-\u03baB pathway through microbiota\u2013gut\u2013brain axis. Acta Pharmaceutica Sinica B. 2021; 11: 2859\u20132879.","DOI":"10.1016\/j.apsb.2021.03.020"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019; 364: eaau6323.","DOI":"10.1126\/science.aau6323"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Wi\u0119ckowska-Gacek A, Mietelska-Porowska A, Wydrych M, Wojda U. Western diet as a trigger of Alzheimer\u2019s disease: from metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Research Reviews. 2021; 70: 101397.","DOI":"10.1016\/j.arr.2021.101397"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Hegelmaier T, Lebbing M, Duscha A, Tomaske L, T\u00f6nges L, Holm JB, et al. Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson\u2019s Disease. Cells. 2020; 9: 376.","DOI":"10.3390\/cells9020376"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Mischley LK, Lau RC, Bennett RD. Role of Diet and Nutritional Supplements in Parkinson\u2019s Disease Progression. Oxidative Medicine and Cellular Longevity. 2017; 2017: 6405278.","DOI":"10.1155\/2017\/6405278"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Yan Z, Yang F, Sun L, Yu J, Sun L, Si Y, et al. Role of gut microbiota-derived branched-chain amino acids in the pathogenesis of Parkinson\u2019s disease: an animal study. Brain, Behavior, and Immunity. 2022; 106: 307\u2013321.","DOI":"10.1016\/j.bbi.2022.09.009"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Jang J, Yeom M, Ahn S, Oh J, Ji S, Kim T, et al. Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson\u2019s disease. Brain, Behavior, and Immunity. 2020; 89: 641\u2013655.","DOI":"10.1016\/j.bbi.2020.08.015"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Zhang X, Pang G, Sun T, Liu X, Pan H, Zhang Y, et al. A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation. Biomaterials. 2023; 294: 122005.","DOI":"10.1016\/j.biomaterials.2023.122005"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology. 2018; 3: 1255\u20131265.","DOI":"10.1038\/s41564-018-0257-9"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/22\/6\/10.31083\/j.jin2206157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:11:18Z","timestamp":1732723878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/22\/6\/10.31083\/j.jin2206157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"alternative-id":["S0219-6352(23)00593-4"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2206157","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"article-number":"157"}}